TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02523898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformine
Description: 1500 mg metformine 8week plus 100 mg clomiphene for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo 8 weeks plus 100 mg clomiphene for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clomiphene citrate
Description: 100 mg clomiphene for 5 days starting from day 3 of their spontaneous menses or withdrawal bleeding induced by progestin administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clomiphene citrate
Description: 100 mg clomiphene for 5 days starting from day 3 of their spontaneous menses or withdrawal bleeding induced by progestin administration
Study: NCT04376710

Intervention type: OTHER
Intervention: Completion of pre-pandemic survey
Description: Surgeons will take a pre-pandemic survey to determine surgeon perceptions to telemedicine and barriers to implementation.

Intervention type: OTHER
Intervention: Completion of survey after peak of pandemic
Description: Surgeons will take another survey after the peak of pandemic to determine surgeon perceptions to telemedicine and barriers to implementation.

Intervention type: OTHER
Intervention: Completion of post telemedicine encounter survey
Description: Patients will take a post telemedicine encounter survey to determine patient perceptions to telemedicine and barriers to implementation.
Study: NCT03872167

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BIPAP, Intelligent automatic mode defined by assured volume with pressure support
Description: Correction of night ventilation through an automatic mode of ventilation with assured volume with pressure support

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BIPAP, manual tritration.
Description: Correction of night ventilation through a manual titration of non-invasive mechanical ventilation using polysomnography.
Study: NCT03053076

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous Umbilical Cord Blood Mononuclear Cells Therapy
Description: Autologous Umbilical Cord Blood Mononuclear Cells Therapy in preterm for safety and effect evaluation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride
Description: 0.9% Sodium Chloride in control group
Study: NCT02793141

Intervention type: OTHER
Intervention: No intervention
Description: No intervention will be administered
Study: NCT03661632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986310
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986310
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study: NCT00459953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended treatment
Description: All participants receive an open label phase treatment that includes nicotine patch and cognitive behavior therapy for a period of 10 weeks. The extended treatment group received an additional 9 sessions of cognitive and behavioral skills training.
Study: NCT01957553

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast test product
Description: Coloplast test product is a newly developed 2-piece ostomy appliance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast test product
Description: Coloplast test product is a newly developed 2-piece ostomy appliance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SenSura
Description: SenSura is the commercial available CE-marked SenSura Click 2-piece ostomy appliance from Coloplast A/S

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SenSura
Description: SenSura is the commercial available CE-marked SenSura Click 2-piece ostomy appliance from Coloplast A/S
Study: NCT01822340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM10560A
Description: Once weekly HM10560A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM10560A
Description: Once weekly HM10560A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM10560A
Description: Once weekly HM10560A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM10560A
Description: Once weekly HM10560A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Genotropin
Description: Once daily Genotropin
Study: NCT03357159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: In the first phase escalated doses of post-transplant cyclophosphamide up to a maximal dose of 50 mg/kg , the second phase will use the MTD cyclophosphamide dose identified in the first phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-human T-lymphocyte immunoglobulin (ATLG)
Description: 15mg/kg total (5mg/kg day) on days -3 to -1 pre transplantation
Study: NCT01906203

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: body bioelectrical impedance performed by Z-Métrix (class IIa) - BIOPARHOM 12 allée des lacs de garde, Savoie Technolac BP 238, 73374 Bourget du lac, France
Study: NCT04426981

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: Behavioral activation is a behavioral treatment that focuses on helping participants engage in more rewarding and enjoyable activities. In the first session, participants will begin to identify domains of their life which are important to them. In the second session, participants will be assisted in creating an action plan to engage in more activities in one or more domains of importance. In session 3-8, participants will be assisted in problem solving any challenges they encountered in implementing their previous action plan and will develop a new action plan. The intervention will continue until participants achieved three action plans or reach the eight-session limit, whichever comes first.
Study: NCT04334551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine
Description: switches from etravirine to doravirine, in experienced HIV patients
Study: NCT03903445

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Masayang Pamilya Para Sa Batang Pilipino Program (MaPa Kids)
Description: MaPa Kids is an 8-session parenting program delivered weekly to groups of parents (N=15 per group).~The program includes the following content: 1) spending one-on-one time with children; 2) describing actions and feelings for cognitive development and socio-emotional awareness; 3) using praise and rewards to encourage positive behavior; 4) establishing limits through effective instruction giving and consistent household rules; 5) nonviolent discipline such as ignoring negative attention seeking behavior, and consequences for noncompliance, rule-breaking, and aggressive behavior; 6) problem solving with children; and 7) mindfulness based stress reduction.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Masayang Pamilya Para Sa Tinedyer Pilipino Program (MaPa Teens)
Description: MaPa Teens is a 9-session parenting program delivered to groups of parents and children aged 10-17 (N=15 dyads per group).~The program includes the following content: 1) one-on-one time with parents and teens, 2) positive reinforcement of positive behavior, 3) managing anger and stress, 4) establishing rules and routines, 5) family budgeting, 6) accepting responsibility for actions, 7) resolving family conflicts, 8) keeping safe in the community and resolving conflicts, and 9) reflection and moving on.
Study: NCT04544254

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral transversus thoracis muscle plane block
Description: The block will be performed in between intercostal space 4 and 5, lateral from sternum, with ultrasound guided. Twenty milliliters bupivacaine 0.5% 1mg/body weight will be injected between internal intercostal muscle and transversus thoracis muscle on both sides.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: A needle will be place in the similar area to the transversus thoracis muscle plane block, but no drugs will be injected to the area
Study: NCT03209687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human menopausal gonadotropin
Description: Merional injections will be given to participants after ovum pickup in in-vitro fertilization cycles
Study: NCT04990154

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: a 12-week intradialytic exercise
Description: a 12-week intradialytic exercise (supine lower-limb ergometer, 30 minutes/session, 3 sessions/week)
Study: NCT00737282

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proellex 25 mg
Description: One capsule Proellex 25 mg administered as daily oral doses for four (4) consecutive months during each treatment cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proellex 50 mg
Description: Two capsules Proellex 25 mg administered as daily oral doses for four (4) consecutive months during each treatment cycle
Study: NCT01275391

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer Screening, Brief Intervention, Referral toTreatment
Description: A computerized screening for tobacco, alcohol and drug use accompanied by 10-15 pages of health information regarding the risks of tobacco, alcohol and drug use. This is followed by a brief conversation with the primary care provider regarding the health risks of tobacco, alcohol and drug use and a referral to treatment for those at high risk of substance use problems.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer Screening, Brief Intervention, Referral toTreatment
Description: A computerized screening for tobacco, alcohol and drug use accompanied by 10-15 pages of health information regarding the risks of tobacco, alcohol and drug use. This is followed by a brief conversation with the primary care provider regarding the health risks of tobacco, alcohol and drug use and a referral to treatment for those at high risk of substance use problems.
Study: NCT03067649

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interview
Description: 90-minute interview to discuss their concerns and possible barriers to seeking treatment for themselves

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Information only control
Description: Participants are provided with a pamphlet containing referral information
Study: NCT01598012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ayurved Siriraj Prasaplai with or without mefenamic acid
Description: Prasaplai in capsule, 2 cap three times a day for 3 days. Mefenamic acid 500 mg prn for severe pain (as rescue medication)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo with or without mefenamic acid
Description: Placebo in capsule (physically identical appearance as Prasaplai) 2 cap three times a day for 3 days. Mefenamic acid 500 mg prn for severe pain, every 6 hours (rescue medication)
Study: NCT00719121

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Talarozole
Description: Topical Application (20 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Talarozole
Description: Topical Application (20 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Differin™, 0.1% adapalene gel
Description: Topical Application (20 mg)
Study: NCT03950648

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spatial Cognitive Training
Description: map reading and route-learning skills
Study: NCT00007657

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensive medical therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intensive medical therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI) plus intensive medical therapy
Study: NCT00191789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1200 mg/m\^2, intravenous (IV) day 1 and day 8 every 21 days x 4 cycles (1-4) then 1000 mg/m\^2, IV, day 1 and day 8 every 21 days x 4 cycles (5-8)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 60 mg/m\^2, IV, every 21 days x 4 cycles (1-4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 70 mg/m\^2, IV, every 21 days x 4 cycles (5-8)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: Surgery follows 8 cycles of chemotherapy. Extent and type of surgery is guided by tumor size, physician and/or patient decision.
Study: NCT05065177

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational live attenuated mumps vaccine
Description: The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: control live attenuated mumps vaccine
Description: The control vaccine was manufactured by Zhejiang VACN bio-pharmaceutical Co. Ltd.
Study: NCT01922206

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRACK Intervention
Description: TRACK Intervention~3-session, individually administered psycho-educational intervention to promote maternal disclosure of HIV status to child
Study: NCT00759811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Patients receiving conventional treatment to heart failure who will receive methotrexate 7.5mg oral plus folic acid 5mg oral once a week for 12 weeks.~All patients will have evaluated at the baseline and after 12 weeks: physical capacity by the 6-minutes walk test, quality of life by the Brazilian edition SF-36 and inflammatory marker by C-reactive protein. They also will be tested for ALT, AST, blood cell count, creatinine, and prothrombin time at baseline, after 6 weeks and after 12 weeks.
Study: NCT01307800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT00759811

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients receiving conventional treatment to heart failure who will receive placebo oral plus folic acid 5mg oral once a week for 12 weeks.~All patients will have evaluated at the baseline and after 12 weeks: physical capacity by the 6-minutes walk test, quality of life by the Brazilian edition SF-36 and inflammatory marker by C-reactive protein. They also will be tested for ALT, AST, blood cell count, creatinine, and prothrombin time at baseline, after 6 weeks and after 12 weeks.
Study: NCT04399577

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candida antigen
Description: Patient receive candida antigen immunotherapy and blood samples will be withdrawn before and after intervention
Study: NCT03847233

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jetstream Atherectomy System
Description: A rotating, aspirating, expandable catheter system for active removal of atherosclerotic debris and thrombus in the SFA and/or PPA
Study: NCT03552198

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alternative health advice
Description: These messages targeted specific beliefs about air pollution and protective actions aimed at reducing exposure to air pollution. In addition, message specificity was targeted, which means that compared to the usual messages, the alternative messages reported more detailed health recommendations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alternative health advice
Description: These messages targeted specific beliefs about air pollution and protective actions aimed at reducing exposure to air pollution. In addition, message specificity was targeted, which means that compared to the usual messages, the alternative messages reported more detailed health recommendations.
Study: NCT02916342

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene brachial plexus block
Description: Patients will receive an ultrasound-guided interscalene brachial plexus block before general anaesthesia.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supraclavicular-axillary nerve blocks
Description: Patients will receive ultrasound-guided supraclavicular and axillary nerve blocks before general anaesthesia.
Study: NCT03719976

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group-based educational intervention
Description: The group-based educational intervention will use a bilingual Community Health Worker (CHW) who will teach parents key skills needed to access health care for children. Parents will be invited to attend 6 small, closed-group sessions held over 12 weeks and lasting no more than 75 minutes. Sessions will be interactive, culturally-appropriate, and held in parents' preferred language.
Study: NCT02972489

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D OFDI guidance arm
Description: Subjects randomized to 3D-guidance arm will undergo optical frequency domain imaging (OFDI) assessment in the main vessel after re-wiring into the jailed side branch following stent implantation. If the position of the wire is not located in the optimal cell, further attempts to redirect the wire to the optimal cell will be performed, with subsequent OFDI acquisitions to confirm position in 2D and off-line 3D reconstruction. After procedure, OFDI is performed in the main branch.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angio guidance arm
Description: In angiography-guidance group, wire recrossing into the side branch will be performed using conventional fluoroscopic/angiographic guidance. After finishing the procedure, OFDI is performed in the main branch but the results will be blinded to the operators.
Study: NCT03334448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014-U200
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014-U100
Description: Administered SC
Study: NCT02425657

Intervention type: BEHAVIORAL
Intervention: Training of junior doctors
Description: Training program
Study: NCT01107041

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobilyze!
Description: Mobilyze! delivers behavioral intervention for depression via a mobile phone, interactive website, and e-mail.
Study: NCT03033381

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Color Doppler Ultrasound
Description: Radiological evaluation was performed by a single radiologist using CDUS for operated side testis of each patient preoperatively and on days 7 and 30 post-surgery. Longitudinal, anteroposterior, and transverse diameters of the testis were measured, and the testicular volume was calculated automatically using the CDUS device (volume = 0.523 × D1 × D2 × D3, where D1, D2, and D3 were the maximal longitudinal, anteroposterior, and transverse diameters defined by CDUS) for both testicles in each patient . Peak systolic velocity (PSV) was calculated using the CDUS system (in cm3/s) for both testicles in each patient.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Color Doppler Ultrasound
Description: Radiological evaluation was performed by a single radiologist using CDUS for nonoperated side testis of each patient preoperatively and on days 7 and 30 post-surgery. Longitudinal, anteroposterior, and transverse diameters of the testis were measured, and the testicular volume was calculated automatically using the CDUS device (volume = 0.523 × D1 × D2 × D3, where D1, D2, and D3 were the maximal longitudinal, anteroposterior, and transverse diameters defined by CDUS) for both testicles in each patient . Peak systolic velocity (PSV) was calculated using the CDUS system (in cm3/s) for both testicles in each patient.
Study: NCT00940251

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mersina
Description: capsule, 3g/day, 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mersina
Description: capsule, 3g/day, 3 months
Study: NCT03933410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KB195
Description: KB195 is a novel glycan
Study: NCT04333511

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TPS (NEUROLITH)
Description: 6 treatments of TPS over 2 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TPS (NEUROLITH)
Description: 6 treatments of TPS over 2 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham-TPS (NEUROLITH)
Description: 6 treatments of Sham-TPS over 2 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham-TPS (NEUROLITH)
Description: 6 treatments of Sham-TPS over 2 weeks
Study: NCT01022372

Intervention type: PROCEDURE
Intervention: Endometrial biopsy
Description: For all the groups

Intervention type: PROCEDURE
Intervention: Endometrial biopsy
Description: For all the groups

Intervention type: PROCEDURE
Intervention: Endometrial biopsy
Description: For all the groups
Study: NCT01701479

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ch14.18/CHO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ch14.18/CHO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotretinoin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Study: NCT02944227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucentis
Description: Lucentis fixed-treatment arm
Study: NCT04272866

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinpro sealant
Description: Resin based sealant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Embrace wetbond sealant
Description: Moisture tolerant hydrophilic resin based sealant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Triage sealant
Description: Glass ionomer sealant
Study: NCT02402439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Islet cells
Description: Transplantation of islets into the gastrointestinal submucosa

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Islet transplantation into the gastrointestinal submucosa
Description: Transplantation of islets into the gastrointestinal submucosa
Study: NCT01329731

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: elmex® gelée
Description: 1.25% fluoride (elmex® gelée) Dosage: Weekly brushing with 0.5g of respective gel Route: Intraoral topical

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: negative control (placebo)
Description: 0% fluoride (negative control) Dosage: Weekly brushing with 0.5g Route: Intraoral topical
Study: NCT03587012

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain fitness app
Description: Daily tutored sessions of brain exercises on an iPAD (in-person or remote)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain fitness app with tACS
Description: Daily tutored sessions of brain exercises on an iPAD with simultaneous transcranial alternating current stimulation (tACS)
Study: NCT00806754

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide nasal spray + placebo Azelastine
Description: Ciclesonide nasal spray 50 mcg + Placebo Azelastine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide nasal spray + Azelastine
Description: Ciclesonide nasal spray 50 mcg + Azelastine 137 mcg